Development of affinity microcolumns for drug-protein binding studies in personalized medicine

Interactions of sulfonylurea drugs with in vivo glycated human serum albumin

Jeanethe Anguizola, K. S. Joseph, Omar S. Barnaby, Ryan Matsuda, Guadalupe Alvarado, William Clarke, Ronald Cerny, David S Hage

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

This report used high-performance affinity microcolumns to examine the changes in binding by sulfonylurea drugs to in vivo glycated HSA that had been isolated from individual patients with diabetes. An immunoextraction approach was developed to isolate HSA and glycated HSA from clinical samples, using only 20 μL of plasma or serum and 6-12 nmol of protein to prepare each affinity microcolumn. It was found that the affinity microcolumns could be used in either frontal analysis or zonal elution studies, which typically required only 4-8 min per run. The microcolumns had good stability and allowed data to be obtained for multiple drugs and experimental conditions over hundreds of sample application cycles. Both the overall binding, as measured by frontal analysis, and site-specific interactions, as examined by zonal elution, showed good agreement with previous data that had been obtained for in vitro glycated HSA with similar levels of modification. It was also possible to directly compare the changes in site-specific binding that occurred between sulfonylurea drugs or as the level of HSA glycation was varied. This method is not limited to clinical samples of glycated HSA but could be adapted for work with other modified proteins of interest in personalized medicine.

Original languageEnglish (US)
Pages (from-to)4453-4460
Number of pages8
JournalAnalytical chemistry
Volume85
Issue number9
DOIs
StatePublished - May 7 2013

Fingerprint

Serum Albumin
Medicine
Pharmaceutical Preparations
Medical problems
Proteins
Plasmas
Protein Binding

ASJC Scopus subject areas

  • Analytical Chemistry

Cite this

Development of affinity microcolumns for drug-protein binding studies in personalized medicine : Interactions of sulfonylurea drugs with in vivo glycated human serum albumin. / Anguizola, Jeanethe; Joseph, K. S.; Barnaby, Omar S.; Matsuda, Ryan; Alvarado, Guadalupe; Clarke, William; Cerny, Ronald; Hage, David S.

In: Analytical chemistry, Vol. 85, No. 9, 07.05.2013, p. 4453-4460.

Research output: Contribution to journalArticle

Anguizola, Jeanethe ; Joseph, K. S. ; Barnaby, Omar S. ; Matsuda, Ryan ; Alvarado, Guadalupe ; Clarke, William ; Cerny, Ronald ; Hage, David S. / Development of affinity microcolumns for drug-protein binding studies in personalized medicine : Interactions of sulfonylurea drugs with in vivo glycated human serum albumin. In: Analytical chemistry. 2013 ; Vol. 85, No. 9. pp. 4453-4460.
@article{690a2e7de1c74781b015e854970b7d67,
title = "Development of affinity microcolumns for drug-protein binding studies in personalized medicine: Interactions of sulfonylurea drugs with in vivo glycated human serum albumin",
abstract = "This report used high-performance affinity microcolumns to examine the changes in binding by sulfonylurea drugs to in vivo glycated HSA that had been isolated from individual patients with diabetes. An immunoextraction approach was developed to isolate HSA and glycated HSA from clinical samples, using only 20 μL of plasma or serum and 6-12 nmol of protein to prepare each affinity microcolumn. It was found that the affinity microcolumns could be used in either frontal analysis or zonal elution studies, which typically required only 4-8 min per run. The microcolumns had good stability and allowed data to be obtained for multiple drugs and experimental conditions over hundreds of sample application cycles. Both the overall binding, as measured by frontal analysis, and site-specific interactions, as examined by zonal elution, showed good agreement with previous data that had been obtained for in vitro glycated HSA with similar levels of modification. It was also possible to directly compare the changes in site-specific binding that occurred between sulfonylurea drugs or as the level of HSA glycation was varied. This method is not limited to clinical samples of glycated HSA but could be adapted for work with other modified proteins of interest in personalized medicine.",
author = "Jeanethe Anguizola and Joseph, {K. S.} and Barnaby, {Omar S.} and Ryan Matsuda and Guadalupe Alvarado and William Clarke and Ronald Cerny and Hage, {David S}",
year = "2013",
month = "5",
day = "7",
doi = "10.1021/ac303734c",
language = "English (US)",
volume = "85",
pages = "4453--4460",
journal = "Analytical Chemistry",
issn = "0003-2700",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Development of affinity microcolumns for drug-protein binding studies in personalized medicine

T2 - Interactions of sulfonylurea drugs with in vivo glycated human serum albumin

AU - Anguizola, Jeanethe

AU - Joseph, K. S.

AU - Barnaby, Omar S.

AU - Matsuda, Ryan

AU - Alvarado, Guadalupe

AU - Clarke, William

AU - Cerny, Ronald

AU - Hage, David S

PY - 2013/5/7

Y1 - 2013/5/7

N2 - This report used high-performance affinity microcolumns to examine the changes in binding by sulfonylurea drugs to in vivo glycated HSA that had been isolated from individual patients with diabetes. An immunoextraction approach was developed to isolate HSA and glycated HSA from clinical samples, using only 20 μL of plasma or serum and 6-12 nmol of protein to prepare each affinity microcolumn. It was found that the affinity microcolumns could be used in either frontal analysis or zonal elution studies, which typically required only 4-8 min per run. The microcolumns had good stability and allowed data to be obtained for multiple drugs and experimental conditions over hundreds of sample application cycles. Both the overall binding, as measured by frontal analysis, and site-specific interactions, as examined by zonal elution, showed good agreement with previous data that had been obtained for in vitro glycated HSA with similar levels of modification. It was also possible to directly compare the changes in site-specific binding that occurred between sulfonylurea drugs or as the level of HSA glycation was varied. This method is not limited to clinical samples of glycated HSA but could be adapted for work with other modified proteins of interest in personalized medicine.

AB - This report used high-performance affinity microcolumns to examine the changes in binding by sulfonylurea drugs to in vivo glycated HSA that had been isolated from individual patients with diabetes. An immunoextraction approach was developed to isolate HSA and glycated HSA from clinical samples, using only 20 μL of plasma or serum and 6-12 nmol of protein to prepare each affinity microcolumn. It was found that the affinity microcolumns could be used in either frontal analysis or zonal elution studies, which typically required only 4-8 min per run. The microcolumns had good stability and allowed data to be obtained for multiple drugs and experimental conditions over hundreds of sample application cycles. Both the overall binding, as measured by frontal analysis, and site-specific interactions, as examined by zonal elution, showed good agreement with previous data that had been obtained for in vitro glycated HSA with similar levels of modification. It was also possible to directly compare the changes in site-specific binding that occurred between sulfonylurea drugs or as the level of HSA glycation was varied. This method is not limited to clinical samples of glycated HSA but could be adapted for work with other modified proteins of interest in personalized medicine.

UR - http://www.scopus.com/inward/record.url?scp=84877318285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877318285&partnerID=8YFLogxK

U2 - 10.1021/ac303734c

DO - 10.1021/ac303734c

M3 - Article

VL - 85

SP - 4453

EP - 4460

JO - Analytical Chemistry

JF - Analytical Chemistry

SN - 0003-2700

IS - 9

ER -